CRIS

Business Context and Reporting Period

Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways for tissue repair and regeneration. The company has no commercial products and relies on strategic collaborations (Genentech, Wyeth, Ortho Biotech) for funding and development. It has incurred an accumulated deficit of approximately $657.4 million as of June 30, 2004.

Key Financial Metrics

Note: Debt includes convertible notes payable to Becton Dickinson and Elan Pharma International, as well as capital lease obligations.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 104% for the three months ended June 30, 2004, compared to the same period in 2003. This was driven by new collaborations with Genentech and Wyeth, offsetting the loss of revenue from the ES Cell International diabetes program which ended in late 2003.
• Expense Reductions: Research and Development (R&D) expenses decreased 18% ($617,000) for the quarter, primarily due to the cessation of the ES Cell program and cost reductions in the nervous system disorders program. However, spending on the cancer program (Genentech collaboration) increased.
• General & Administrative (G&A): G&A expenses increased 37% ($601,000) for the quarter, attributed to costs associated with a postponed equity financing, technology acquisition evaluations, and increased personnel.
• Net Loss Improvement: Net loss decreased by approximately 13% for the six-month period compared to the prior year, despite higher revenues, due to the elimination of preferred stock accretion charges present in 2003.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing capital resources (cash, equivalents, and marketable securities totaling ~$30.9 million) are sufficient to fund operations into the second half of 2006. However, this assumes the company does not exercise its co-development option with Genentech for a basal cell carcinoma candidate, which would require additional funding.
• Strategic Decisions: The company expects to receive a co-development plan from Genentech in late 2004 and must decide by Q1 2005 whether to co-develop the basal cell carcinoma candidate. Exercising this option would forego milestone/royalty payments in exchange for shared costs and profits.
• Revenue Recognition: Revenue is recognized over the performance period of collaboration agreements. Significant deferred revenue ($9.1 million total) is recorded based on estimates of the time required to commercialize candidates.
• Risks: Key risks include the failure to achieve regulatory approval, dependence on collaborators for development and commercialization, potential impairment of investments in privately-held companies (e.g., Micromet), and the need for additional financing if the Genentech co-development option is exercised or if cash burn accelerates.

Investor Verification Checklist

• Genentech Co-Development Decision: Verify the timeline and financial impact of the decision regarding the basal cell carcinoma co-development option expected in Q1 2005.
• Deferred Revenue Estimates: Review the assumptions regarding the "period of involvement" used to amortize license fees from Genentech and Wyeth, as changes in clinical timelines could alter future revenue recognition.
• Investment Valuation: Monitor the financial health of privately-held investments (Aegera, Micromet, ES Cell International) for potential impairment charges.
• Debt Covenants and Maturities: Confirm compliance with debt covenants and the status of the convertible notes payable to Becton Dickinson and Elan Pharma International.
• Cash Burn Rate: Track the monthly cash burn rate to ensure it aligns with the projection of funding operations through mid-2006 without additional equity or debt financing.